Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scynexis names new CEO

This article was originally published in Scrip

Executive Summary

Drug discovery and development company Scynexis has appointed Dr Marco Taglietti CEO, effective from 1 April 2015. Dr Taglietti, a member of Scynexis' board of directors, will succeed Dr Yves Ribeill in the position. Dr Ribeill will remain the company's president and will continue to serve on the company's board. In an unrelated matter Scynexis said Dr Carole Sable, the company's current chief medical officer, is stepping down effective 20 February 2015.

Advertisement
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC027823

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel